We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

TPW:GETTEXTrupanion, Inc. Analysis

Data as of 2026-03-15 - not real-time

€21.45

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Trupanion’s stock is trading at €21.45, barely above the computed support level of €21.13 and well below its 20‑day (≈€23.04), 50‑day (≈€25.97) and 200‑day (≈€35.21) moving averages, signaling a bearish technical backdrop. The RSI sits at 36, hinting at mild oversold conditions, while the MACD histogram remains negative, reinforcing downside momentum. Volatility is extreme at 63% over the past 30 days and beta exceeds 1, indicating the stock moves more sharply than the market. On the fundamentals side, revenue grew 11.7% year‑over‑year to $1.44 bn, yet gross margin is only 22.6% and net profit margin a meager 1.35%, with free cash flow turning negative. The price‑to‑earnings multiple of 55 dwarfs the industry average of 16, suggesting the market is pricing in high expectations, but the discounted cash‑flow model estimates a fair value of €37.48, implying a substantial upside. The company carries modest debt (Debt‑to‑Equity ≈33%) and does not pay a dividend. Historical max drawdown of –57% and a thin daily volume (≈46 shares) highlight liquidity concerns. Overall, the stock appears undervalued relative to intrinsic estimates but faces significant short‑term technical pressure and high volatility. Investors should weigh the upside potential against the pronounced risk profile.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • price hovering just above support
  • bearish MACD and SMA alignment
  • high short‑term volatility

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • 11.7% revenue growth trajectory
  • DCF fair value indicating ~€16 upside
  • potential margin improvement as scale increases

Long Term

> 3 years
Positive
Model confidence: 6/10

Key Factors

  • expanding pet‑insurance market globally
  • undervalued intrinsic valuation vs current price
  • manageable debt load and strong cash position

Key Metrics & Analysis

Financial Health

Revenue Growth11.70%
Profit Margin1.35%
P/E Ratio55.0
ROE5.50%
ROA1.11%
Debt/Equity32.80
P/B Ratio2.8
Op. Cash Flow€89.5M
Free Cash Flow€-23275000
Industry P/E16.4

Technical Analysis

TrendBearish
RSI36.3
Support€21.13
Resistance€24.84
MA 20€23.04
MA 50€25.97
MA 200€35.21
MACDBearish
VolumeStable
Fear & Greed Index72.88

Valuation

Fair Value€37.48
GradeUndervalued
TypeGrowth

Risk Assessment

Beta1.12
Volatility63.61%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskHigh

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.